News
XAIR
2.840
+0.71%
0.020
Weekly Report: what happened at XAIR last week (0921-0925)?
Weekly Report · 09/28 10:06
Beyond Air Slips After Disclosure of Long-Term Employment Contract for CEO
Dow Jones · 09/24 21:34
Beyond Air Formalizes CEO Agreement, Boosts CFO Compensation
TipRanks · 09/24 21:04
Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".
Benzinga · 09/24 20:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 09/21 21:06
Weekly Report: what happened at XAIR last week (0914-0918)?
Weekly Report · 09/21 10:06
Weekly Report: what happened at XAIR last week (0907-0911)?
Weekly Report · 09/14 10:11
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 09/11 21:06
Weekly Report: what happened at XAIR last week (0831-0904)?
Weekly Report · 09/07 10:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/01 21:06
Beyond Air Price Target Announced at $10.00/Share by Lake Street
Dow Jones · 09/01 19:00
Lake Street Initiates Coverage On Beyond Air with Buy Rating, Announces Price Target of $10
Benzinga · 09/01 18:51
Beyond Air initiated with a Buy at Lake Street on durable recurring revenue
TipRanks · 09/01 12:45
Beyond Air initiated with a Buy at Lake Street
TipRanks · 09/01 12:26
Beyond Air Receives FDA Breakthrough Device Designation For LungFit GO In NTM-PD
NASDAQ · 08/31 12:42
Beyond Air gets Breakthrough Device Designation for LungFit GO
TipRanks · 08/31 12:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/31 12:06
Weekly Report: what happened at XAIR last week (0824-0828)?
Weekly Report · 08/31 10:11
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 08/28 17:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 08/28 12:06
More
Webull provides a variety of real-time XAIR stock news. You can receive the latest news about Beyond Air Inc through multiple platforms. This information may help you make smarter investment decisions.
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.